If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
658.00    -19.00 (-2.81%)
Bid:
656.00
Ask:
660.00
Spread: 4.00 (0.61%)
Market Cap: £573.28m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

AGM & Q1 Interim Management Statement

10 Feb 2023 07:00

RNS Number : 5110P
Victrex PLC
10 February 2023
 
 

10 February 2023

Victrex plc - AGM & Q1 Interim Management Statement

'A steady start: pricing ahead of expectations and revenue up 6%, despite volume softness'

Victrex plc is an innovative world leader in high performance polymer solutions, delivering sustainable products which enable environmental and societal benefit in multiple end-markets. Today's Interim Management Statement (IMS) covers the first quarter of FY 2023 from 1 October 2022 to 31 December 2022.

 

Overall, the Group saw a steady start, in what is typically the seasonally weakest quarter. Average selling prices (ASP) were ahead of expectations, with good momentum from price increases and surcharge pricing. This helped to drive revenue up 6%, despite an 8% decline in Q1 volume; slightly softer than anticipated.

Highlights

· Q1 Group revenue £78.8m up 6% (Q1 2022: £74.6m)

· ASP up 14% at £83/kg and slightly ahead of expectations; driven by sales mix, annualised price increases, surcharge pricing and currency

· Q1 Group sales volume of 948 tonnes down 8% on the prior year (Q1 2022: 1,025 tonnes)

· Supporting TechnipFMC for Brazil scale-up ahead of bid outcome for Magma pipe opportunity

· Share buybacks now included alongside special dividends for excess cash return options, following shareholder engagement

 

End market performance

Q1 performance reflected reduced activity across several Industrial end markets, particularly in Europe, together with some normalisation within Value Added Resellers (VAR) after a period of strong growth. The Group saw growth in Aerospace and Automotive during the period, which was offset by weakness in Electronics and Energy & Industrial.

 

In Medical, we continue to see a good performance. Q1 revenue was strongly ahead of the comparative period, which included the impact of Covid-19 variants and lockdowns in the US, in Europe and Asia.

 

Mega-programmes

The Group has an attractive portfolio of short, medium and long-term growth opportunities, including seven 'mega-programmes' offering potentially game changing growth opportunities. 

 

In our Magma mega-programme, which is based on thermoplastic composite pipe for the energy industry using Victrex PEEK, Victrex composite tape and Victrex's pipe extrusion know-how, we continue to support TechnipFMC for qualification and scale-up at a new facility in Brazil. Bid outcomes for a key offshore programme in Brazil are anticipated over the coming months, offering the potential opportunity for significant annual volumes, over a multi-year period.

 

In our PEEK Knee mega-programme, we have seen further strong progress. Patient recruitment to the Maxx Orthopaedics clinical trial is largely complete, with 33 implanted patients. Ten patients have passed the primary end-point for the clinical trial (15 months), with no issues or intervention required. Two patients will pass the two-year implant stage this month. In Trauma, In2Bones has continued to make strong progress, with our PEEK composite based Trauma plates now being implanted in over 80 patients.

 

Financial position

Victrex retains a highly cash generative business model, supporting growth investment alongside attractive shareholder returns. Available cash of £60.8m at 31 December 2022 (excluding £2.3m of cash ringfenced in our Chinese subsidiaries), is prior to payment of the 2022 final dividend on 17 February. 

 

Outlook

Jakob Sigurdsson, Chief Executive of Victrex, said: "Expectations for the full year are unchanged at this early stage. We are encouraged by modest revenue growth, a better sales mix and improved selling prices. We also continue to make good progress in recovering energy and raw material inflation.

 

"However, the Group saw softer volumes during Q1 and the macro-economic environment remains uncertain, with ongoing weakness in several end-markets. In line with Victrex's historic performance, we remain well positioned for when end-markets improve.

 

"With sustainable products and a strong pipeline of growth opportunities, our Polymer & Parts strategy keeps us well positioned for the medium to long-term."

 

Analyst & investor conference call

A conference call with management will take place this morning, Friday 10th February 2023, at 08.30am GMT. Access to the call is via the following link: https://cossprereg.btci.com/prereg/key.process?key=PYTAVPVQF

 

Annual General Meeting

Victrex's Annual General Meeting will also be held today, starting at 11.00am GMT and taking place at JP Morgan, 1 John Carpenter Street, London EC4Y 0JP.

 

Victrex plc:

Andrew Hanson, Director of Investor Relations, Corporate Communications & ESG +44 (0)7809 595831

Ian Melling, Chief Financial Officer +44 (0)1253 897700

Jakob Sigurdsson, Chief Executive +44 (0)1253 897700

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aeroplanes and cars to energy operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, enable environmental and societal benefit for our customers and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRFUPUPCPUPWGRB
Date   Source Headline
8th Dec 20171:19 pmRNSDirector/PDMR Shareholding
5th Dec 201711:39 amRNSDirector/PDMR Shareholding
5th Dec 20177:01 amRNSDirectorate Change
5th Dec 20177:00 amRNSFinal Results
1st Dec 201712:51 pmRNSBlock listing Interim Review
30th Nov 20171:41 pmRNSTotal Voting Rights
27th Nov 201711:20 amRNSAdditional Listing
17th Nov 20173:57 pmRNSDirector/PDMR Shareholding
31st Oct 20179:41 amRNSTotal Voting Rights
17th Oct 20173:29 pmRNSDirector/PDMR Shareholding
29th Sep 201710:31 amRNSTotal Voting Rights
19th Sep 20172:59 pmRNSDirector/PDMR Shareholding
4th Sep 20177:01 amRNSCEO-designate update
4th Sep 20177:00 amRNSReduction in effective tax rate
31st Aug 20173:31 pmRNSTotal Voting Rights
17th Aug 201711:39 amRNSDirector/PDMR Shareholding
31st Jul 201710:36 amRNSTotal Voting Rights
25th Jul 20177:00 amRNSTrading Statement
18th Jul 20172:10 pmRNSDirector/PDMR Shareholding
30th Jun 20172:09 pmRNSTotal Voting Rights
19th Jun 20174:18 pmRNSDirector/PDMR Shareholding
1st Jun 20179:51 amRNSBlock listing Interim Review
31st May 20179:22 amRNSTotal Voting Rights
31st May 20179:05 amRNSHolding(s) in Company
19th May 20179:39 amRNSAdditional Listing
18th May 201710:23 amRNSDirector/PDMR Shareholding
15th May 20177:00 amRNSHalf-year Report
28th Apr 20172:39 pmRNSTotal Voting Rights
19th Apr 20172:17 pmRNSDirector/PDMR Shareholding
19th Apr 20177:57 amRNSDirectorate Change
6th Apr 20177:00 amRNSAcquisition
31st Mar 201710:32 amRNSTotal Voting Rights
28th Mar 20177:00 amRNSCapital Markets Day
24th Mar 20172:44 pmRNSHolding(s) in Company
17th Mar 20172:12 pmRNSDirector/PDMR Shareholding
17th Mar 20179:34 amRNSHolding(s) in Company
14th Mar 201710:56 amRNSHolding(s) in Company
9th Mar 20174:33 pmRNSHolding(s) in Company
28th Feb 201710:49 amRNSTotal Voting Rights
17th Feb 201711:30 amRNSDirector/PDMR Shareholding
8th Feb 20171:59 pmRNSResult of AGM
8th Feb 20179:00 amRNSAudit Tender Notification
8th Feb 20177:00 amRNSAGM Statement
31st Jan 20173:54 pmRNSTotal Voting Rights
17th Jan 20172:52 pmRNSDirector/PDMR Shareholding
5th Jan 201711:31 amRNSAnnual Financial Report
30th Dec 201611:37 amRNSHolding(s) in Company
30th Dec 201610:00 amRNSTotal Voting Rights
21st Dec 20169:14 amRNSDirector Declaration
19th Dec 201612:54 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.